Literature DB >> 27388288

Cytokine Therapies in Neurological Disease.

Shila Azodi1, Steven Jacobson2.   

Abstract

Cytokines are a heterogeneous group of glycoproteins that coordinate physiological functions. Cytokine deregulation is observed in many neurological diseases. This article reviews current research focused on human clinical trials of cytokine and anticytokine therapies in the treatment of several neurological disease including stroke, neuromuscular diseases, neuroinfectious diseases, demyelinating diseases, and neurobehavioral diseases. This research suggests that cytokine therapy applications may play an important role in offering new strategies for disease modulation and treatment. Further, this research provides insights into the causal link between cytokine deregulation and neurological diseases.

Entities:  

Keywords:  Cytokine; anticytokine; drug development.; neurology

Mesh：

Substances：

Year:  2016        PMID： 27388288      PMCID： PMC4965417          DOI： 10.1007/s13311-016-0455-1

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  56 in total

1.  An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Ralph L Sacco; Scott E Kasner; Joseph P Broderick; Louis R Caplan; J J Buddy Connors; Antonio Culebras; Mitchell S V Elkind; Mary G George; Allen D Hamdan; Randall T Higashida; Brian L Hoh; L Scott Janis; Carlos S Kase; Dawn O Kleindorfer; Jin-Moo Lee; Michael E Moseley; Eric D Peterson; Tanya N Turan; Amy L Valderrama; Harry V Vinters
Journal:  Stroke       Date:  2013-05-07       Impact factor: 7.914

2.  Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study.

Authors:  Adriano Chiò; Gabriele Mora; Vincenzo La Bella; Claudia Caponnetto; Gianluigi Mancardi; Mario Sabatelli; Gabriele Siciliano; Vincenzo Silani; Massimo Corbo; Cristina Moglia; Andrea Calvo; Roberto Mutani; Sergio Rutella; Francesca Gualandi; Mario Melazzini; Rosanna Scimè; Mario Petrini; Paola Bondesan; Silvia Garbelli; Stefania Mantovani; Caterina Bendotti; Corrado Tarella
Journal:  Muscle Nerve       Date:  2011-02       Impact factor: 3.217

3.  Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Nafiseh Toghianifar; Fereshteh Ashtari; Sayyed Hamid Zarkesh-Esfahani; Marjan Mansourian
Journal:  J Neuroimmunol       Date:  2015-06-12       Impact factor: 3.478

4.  Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.

Authors:  J Mellergård; M Edström; M Vrethem; J Ernerudh; C Dahle
Journal:  Mult Scler       Date:  2009-12-09       Impact factor: 6.312

5.  Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial.

Authors:  E Bernd Ringelstein; Vincent Thijs; Bo Norrving; Angel Chamorro; Franz Aichner; Martin Grond; Jeff Saver; Rico Laage; Armin Schneider; Frank Rathgeb; Gerhard Vogt; Gabriele Charissé; Jochen B Fiebach; Stefan Schwab; Wolf R Schäbitz; Rainer Kollmar; Marc Fisher; Miroslav Brozman; David Skoloudik; Franz Gruber; Joaquin Serena Leal; Roland Veltkamp; Martin Köhrmann; Jörg Berrouschot
Journal:  Stroke       Date:  2013-08-20       Impact factor: 7.914

6.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Authors:  Bibiana Bielekova; Thomas Howard; Amy N Packer; Nancy Richert; Gregg Blevins; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Arch Neurol       Date:  2009-04

7.  Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.

Authors:  Giuseppe Lauria; Eleonora Dalla Bella; Giovanni Antonini; Giuseppe Borghero; Margherita Capasso; Claudia Caponnetto; Adriano Chiò; Massimo Corbo; Roberto Eleopra; Raffaella Fazio; Massimiliano Filosto; Fabio Giannini; Enrico Granieri; Vincenzo La Bella; Giancarlo Logroscino; Jessica Mandrioli; Letizia Mazzini; Maria Rosaria Monsurrò; Gabriele Mora; Vladimiro Pietrini; Rocco Quatrale; Romana Rizzi; Fabrizio Salvi; Gabriele Siciliano; Gianni Sorarù; Paolo Volanti; Irene Tramacere; Graziella Filippini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-01-16       Impact factor: 10.154

8.  The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial.

Authors:  Navneet Singh; Stephen J Hopkins; Sharon Hulme; James P Galea; Margaret Hoadley; Andy Vail; Peter J Hutchinson; Samantha Grainger; Nancy J Rothwell; Andrew T King; Pippa J Tyrrell
Journal:  J Neuroinflammation       Date:  2014-01-03       Impact factor: 8.322

Review 9.  Interleukin-6, a major cytokine in the central nervous system.

Authors:  María Erta; Albert Quintana; Juan Hidalgo
Journal:  Int J Biol Sci       Date:  2012-10-25       Impact factor: 6.580

10.  Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study.

Authors:  André Maier; Nikolaus Deigendesch; Kathrin Müller; Jochen H Weishaupt; Alexander Krannich; Robert Röhle; Felix Meissner; Kaaweh Molawi; Christoph Münch; Teresa Holm; Robert Meyer; Thomas Meyer; Arturo Zychlinsky
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240
View more
  9 in total

1.  Effects of omega-3 fatty acids supplementation on inflammatory parameters after chronic administration of L-tyrosine.

Authors:  Rafaela Antonini; Giselli Scaini; Monique Michels; Mariane B D Matias; Patrícia F Schuck; Gustavo C Ferreira; Jade de Oliveira; Felipe Dal-Pizzol; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2019-12-11       Impact factor: 3.584

2.  Rg3-enriched Korean Red Ginseng extract inhibits blood-brain barrier disruption in an animal model of multiple sclerosis by modulating expression of NADPH oxidase 2 and 4.

Authors:  Min Jung Lee; Jong Hee Choi; Jinhee Oh; Young Hyun Lee; Jun-Gyo In; Byung-Joon Chang; Seung-Yeol Nah; Ik-Hyun Cho
Journal:  J Ginseng Res       Date:  2020-09-11       Impact factor: 6.060

Review 3.  Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke.

Authors:  Aldo Bonaventura; Luca Liberale; Alessandra Vecchié; Matteo Casula; Federico Carbone; Franco Dallegri; Fabrizio Montecucco
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

4.  Multiple Sclerosis Gene Therapy with Recombinant Viral Vectors: Overexpression of IL-4, Leukemia Inhibitory Factor, and IL-10 in Wharton's Jelly Stem Cells Used in EAE Mice Model.

Authors:  Ahmad Hosseini; Hajar Estiri; Haleh Akhavan Niaki; Akram Alizadeh; Baharak Abdolhossein Zadeh; Sayyed Mohammad Hossein Ghaderian; Akbar Farjadfar; Ali Fallah
Journal:  Cell J       Date:  2017-08-19       Impact factor: 2.479

Review 5.  Production and Application of Multicistronic Constructs for Various Human Disease Therapies.

Authors:  Alisa A Shaimardanova; Kristina V Kitaeva; Ilmira I Abdrakhmanova; Vladislav M Chernov; Catrin S Rutland; Albert A Rizvanov; Daria S Chulpanova; Valeriya V Solovyeva
Journal:  Pharmaceutics       Date:  2019-11-06       Impact factor: 6.321

Review 6.  Selective autophagy as a therapeutic target for neurological diseases.

Authors:  Weilin Xu; Umut Ocak; Liansheng Gao; Sheng Tu; Cameron J Lenahan; Jianmin Zhang; Anwen Shao
Journal:  Cell Mol Life Sci       Date:  2020-10-16       Impact factor: 9.261

7.  Cytokine biomarkers associated with clinical cases of acute flaccid myelitis.

Authors:  William C Weldon; Kun Zhao; Heather A Jost; Kimbell Hetzler; Jessica Ciomperlik-Patton; Jennifer L Konopka-Anstadt; M Steven Oberste
Journal:  J Clin Virol       Date:  2020-08-18       Impact factor: 14.481

Review 8.  The Innate Immune System and Inflammatory Priming: Potential Mechanistic Factors in Mood Disorders and Gulf War Illness.

Authors:  Kyle J Trageser; Maria Sebastian-Valverde; Sean X Naughton; Giulio Maria Pasinetti
Journal:  Front Psychiatry       Date:  2020-07-23       Impact factor: 4.157

Review 9.  Neuroinflammation Treatment via Targeted Delivery of Nanoparticles.

Authors:  Susana R Cerqueira; Nagi G Ayad; Jae K Lee
Journal:  Front Cell Neurosci       Date:  2020-09-30       Impact factor: 5.505
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.